940 Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Euroapi S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.40 |
| 52 Week High | €4.52 |
| 52 Week Low | €2.30 |
| Beta | 0.65 |
| 1 Month Change | -12.26% |
| 3 Month Change | -23.54% |
| 1 Year Change | -11.62% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 940 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.7% | 2.1% | 2.4% |
| 1Y | -11.6% | -23.4% | 2.0% |
Return vs Industry: 940 exceeded the German Pharmaceuticals industry which returned -23.4% over the past year.
Return vs Market: 940 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 940 volatility | |
|---|---|
| 940 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 940 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 940's weekly volatility (7%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3,187 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances, as well as lipids. It offers their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization.
Euroapi S.A. Fundamentals Summary
| 940 fundamental statistics | |
|---|---|
| Market cap | €232.36m |
| Earnings (TTM) | -€130.60m |
| Revenue (TTM) | €919.20m |
0.3x
P/S Ratio-1.8x
P/E RatioIs 940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 940 income statement (TTM) | |
|---|---|
| Revenue | €919.20m |
| Cost of Revenue | €776.80m |
| Gross Profit | €142.40m |
| Other Expenses | €273.00m |
| Earnings | -€130.60m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 29, 2025
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 15.49% |
| Net Profit Margin | -14.21% |
| Debt/Equity Ratio | 5.1% |
How did 940 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 03:25 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Euroapi S.A. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Parkes | BNP Paribas Exane |
| Gary Steventon | BNP Paribas Exane |
| Ben Spruntulis | BNP Paribas Exane |